{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:14:00Z","timestamp":1781968440120,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>ACA-positive interstitial lung disease (ILD) in SSc is traditionally considered less aggressive than anti-topo I antibody (ATA)-positive ILD. However, its clinical profile and prognosis remain poorly defined. We aimed to characterize ACA-associated SSc-ILD and compare it with other serological subsets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicentre cross-sectional observational study including 76 ACA-positive SSc-ILD patients, compared with ATA-positive (n\u2009=\u200954) and ACA\/ATA-negative (n\u2009=\u2009147) groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ACA-positive patients developed ILD earlier than ATA-positive and ACA\/ATA-negative individuals (2.5 vs 5.6 and 3.5\u2009years; P\u2009=\u20090.389). Compared with the other groups, they had higher pFVC (96.3% vs 83.5% and 86.9%; P\u2009=\u20090.013), lower pFEV1\/pFVC ratio (91.6% vs 99.2% and 98.8%; P\u2009=\u20090.004) and better functional capacity, with fewer NYHA class III\u2013IV patients (14.5% vs 42.6% and 32%; P\u2009=\u20090.017). They also showed lower pKCO (71.7% vs 85.1% and 77.4%; P\u2009=\u20090.008) and higher pFVC\/pDLCO ratio (1.8 vs 1.4 and 1.5; P\u2009=\u20090.016), suggesting indolent microvascular damage and increased pulmonary vascular resistance. Differences in pDLCO were not significant (60.2% vs 60.9% and 65.7%; P\u2009=\u20090.769). ILD worsening (ATS criteria) occurred in 14.5% of ACA-positive patients. No significant differences were found in antifibrotic indication or advanced interventions. However, 2.6% underwent lung transplantation (0% ATA-positive, 1.4% ACA\/ATA-negative) and 2.6% received autologous haematopoietic stem cell transplantation (0% and 3.4%, respectively). Overall survival analysis revealed no significant differences across the three groups (P\u2009=\u20090.164), although ACA\/ATA-negative patients showed better survival than ACA-positive patients (P\u2009=\u20090.041; HR 0.498, P\u2009=\u20090.045).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ACA-positive SSc-ILD does not seem to have a more favourable long-term prognosis compared with other serological subsets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf407","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:41:09Z","timestamp":1753962069000},"page":"6122-6131","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the clinical spectrum of ACA-positive SSC-ILD: not as benign as expected"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3059-4347","authenticated-orcid":false,"given":"Carlos","family":"Valera-Ribera","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario Dr Peset , Valencia,","place":["Spain"]},{"name":"Faculty of Medicine and Health Sciences, Universitat de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Alegre-Sancho","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario Dr Peset , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-5807","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Castellv\u00ed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario de la Santa Creu i Sant Pau , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario de la Santa Creu i Sant Pau , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Universitat de Barcelona , Barcelona,","place":["Spain"]},{"name":"Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025120216030754600_keaf407-B1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025120216030754600_keaf407-B2","first-page":"S51","article-title":"Pathogenesis of systemic sclerosis-associated interstitial lung disease","volume":"33","author":"Crestani","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025120216030754600_keaf407-B3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated ILD","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025120216030754600_keaf407-B4","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2025120216030754600_keaf407-B5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025120216030754600_keaf407-B6","doi-asserted-by":"crossref","first-page":"152606","DOI":"10.1016\/j.semarthrit.2024.152606","article-title":"Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: a systematic literature review and meta-analysis","volume":"70","author":"Binda","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216030754600_keaf407-B7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025120216030754600_keaf407-B8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025120216030754600_keaf407-B9","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025120216030754600_keaf407-B10","doi-asserted-by":"publisher","first-page":"jrheum.2024-1063","DOI":"10.3899\/jrheum.2024-1063","article-title":"Outcomes in systemic sclerosis-associated interstitial lung disease based on serological profiles: focus on anti-centromere and anti-RNA polymerase III antibodies","volume":"15","author":"Volkmann","year":"2025","journal-title":"J Rheumatol"},{"key":"2025120216030754600_keaf407-B11","doi-asserted-by":"crossref","first-page":"152667","DOI":"10.1016\/j.semarthrit.2025.152667","article-title":"The prognostic power of anti-topoisomerase I and anti-centromere antibodies in systemic sclerosis\u2014a systematic review of the literature","volume":"72","author":"Hoekstra","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216030754600_keaf407-B12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/1756-185X.14206","article-title":"Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis","volume":"24","author":"Qiu","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2025120216030754600_keaf407-B13","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"35","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025120216030754600_keaf407-B14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025120216030754600_keaf407-B15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary consensus classification of the idiopathic interstitial pneumonias","volume":"165","author":"American Thoracic Society, European Respiratory Society","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120216030754600_keaf407-B16","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2025120216030754600_keaf407-B17","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120216030754600_keaf407-B18","doi-asserted-by":"crossref","first-page":"180101","DOI":"10.1183\/16000617.0101-2018","article-title":"ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases","volume":"28","author":"Radtke","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2025120216030754600_keaf407-B19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120216030754600_keaf407-B20","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120216030754600_keaf407-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120216030754600_keaf407-B22","doi-asserted-by":"publisher","first-page":"H1373","DOI":"10.1152\/ajpheart.00157.2013","article-title":"Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis","volume":"305","author":"Guazzi","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025120216030754600_keaf407-B23","doi-asserted-by":"publisher","first-page":"2000513","DOI":"10.1183\/13993003.00513-2020","article-title":"A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension","volume":"56","author":"Ghio","year":"2020","journal-title":"Eur Respir J"},{"key":"2025120216030754600_keaf407-B24","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2025120216030754600_keaf407-B25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.reuma.2022.10.003","article-title":"Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study","volume":"19","author":"Enghelmayer","year":"2023","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2025120216030754600_keaf407-B26","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025120216030754600_keaf407-B27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"2025120216030754600_keaf407-B28","doi-asserted-by":"crossref","first-page":"e003715","DOI":"10.1136\/rmdopen-2023-003715","article-title":"Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study","volume":"10","author":"Hui","year":"2024","journal-title":"RMD Open"},{"key":"2025120216030754600_keaf407-B29","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/diagnostics12051067","article-title":"Autoantibodies versus skin fibrosis extent in systemic sclerosis: a case-control study of inverted phenotypes","volume":"12","author":"Tieu","year":"2022","journal-title":"Diagnostics (Basel)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf407\/63900580\/keaf407.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6122\/63900580\/keaf407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6122\/63900580\/keaf407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:03:14Z","timestamp":1764709394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/12\/6122\/8219966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,31]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf407","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,31]]}}}